Switzerland· 69578002
Ximluci 10 mg/ml, Injektionslösung
A ranibizumab product containing ranibizumabum, registered in Switzerland by Spirig HealthCare AG and dispensed under Swissmedic category B. The same ATC class is registered in 15 of our 19 countries.
Checked against Swissmedic (Switzerland) on
Informational only — not a medical device.
Where it is registered
Ranibizumab is registered in 15 of 19 countries.
Countries holding a registration under ATC S01LA04 (ranibizumab), each read from that country’s own register.
- This record: Switzerland, from Swissmedic (Switzerland)
- 9 of them publish a price we can compare per daily dose
Ranibizumab · ATC S01LA04
15 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
Swissmedic (Switzerland)- Active substance
- ranibizumabum
- Manufacturer
- Spirig HealthCare AG
- Country
- Switzerland (CH)
- ATC code
- S01LA04
- ATC class
- Ranibizumab
- Defined daily dose
- 0.036 DE, IVT
- Swissmedic category
- B
- Reimbursed
- No
- Source register
- Swissmedic (Switzerland)
- Last checked
- September 12, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Ranibizumab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaBYOOVIZSamsung Bioepis NL B.V., Delft
- SwedenByooviz 10 mg/ml Injektionsvätska, lösningSamsung Bioepis NL B.V.
- BelgiumByooviz 10 mg/mlSamsung Bioepis NL
- SpainBYOOVIZ 10 MG/ML SOLUCION INYECTABLESamsung Bioepis Nl B.V.
- PolandByoovizSamsung Bioepis NL B.V.
- NetherlandsByooviz 10 mg/ml, oplossing voor injectieSamsung Bioepis NL B.V.
- IcelandByoovizSamsung Bioepis NL B.V.
- IrelandByooviz 10 mg/ml solution for injectionSamsung Bioepis NL B.V.
Authorised across Europe · EMA
The same active substance is authorised in 4 EEA countries. Names it is sold under:
- United Kingdom (Northern Ireland) · Ximluci
- Iceland · Epruvy, Lucentis
- Liechtenstein · Epruvy, Lucentis
- Norway · Epruvy, Lucentis
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/be22f6b4-44e8-4989-8427-3ab297c51090 GET /v1/drugs/be22f6b4-44e8-4989-8427-3ab297c51090?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{}See everything about ranibizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.